Intravenous Iron Sucrose versus Intramuscular Iron Sorbitol in management of iron deficiency anemia during pregnancy

Background: The greatest prevalent nutrient shortage in pregnant women across the globe is iron deficiency anemia (IDA). Maternal anemia continues to significantly increase neonatal morbidity and death, and there is worry over the elevated incidence of iron and other micronutrient deficiencies among pregnant women in poor nations. Aim of the work: To examine the effectiveness and safety of intramuscular iron sorbitol citric acid complex and intravenous iron sucrose in the treating of iron deficiency anemia (IDA) in gestation. Patients and methods: At the Department of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, 100 pregnant women were separated into two groups for this randomized controlled trial. Between July 2021 and December 2021, 50 pregnant women were separated into two groups: group A got intravenous iron sucrose treatment, while group B got intramuscular iron sorbitol medication. Results: Regarding the negative effects of the therapy, there was a statistically substantial variation between the two trial groups. Conclusion: We concluded that for treating mild anemia in pregnancy, intravenous iron sucrose treatment was shown to be both substantially more efficient and safer than intramuscular iron sorbitol citrate therapy.